Matteo Clavarezza

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 325 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Outcome of Patients with HER2-Positive Advanced Breast Cancer Progressing During Trastuzumab-Based Therapy

Filippo Montemurro, Michela Donadio, Matteo Clavarezza et al. · The Oncologist · 2006 · 128 citations · Full text

Medicine, Oncology, Pharmacology +16

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With <i>RAS</i> Wild-Type Metastatic Colorectal Cancer

Filippo Pietrantonio, Federica Morano, Salvatore Corallo et al. · JAMA Oncology · 2019 · 111 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Negative Hyperselection of Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy

Federica Morano, Salvatore Corallo, Sara Lonardi et al. · Journal of Clinical Oncology · 2019 · 110 citations · Full text

Medicine, Oncology, Pharmacology +17

Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients

Lucia Del Mastro, T. Catzeddu, Luca Boni et al. · Annals of Oncology · 2005 · 106 citations · Full text

Medicine, Gynecology, Oncology +15